To the challenges presented to the healthcare logistics sector over the past year (and more) PHSE will try to give a multifaceted response in 2023.

“In the first half of the year we will open a new strategic node in Bologna, to rebalance incoming shipments from the North towards the Adriatic ridge and thus decongest the Lazio hub. In addition, we will change our headquarters in Campania, moving to one that will have ten times more space than the current one,” announced the quality manager of the company – three of the most important in Italy in the logistics management of clinical trials, pharmaceuticals, biotechnology, and biological samples – Paolo Gagliardi La Gala, during the conference ‘Healthcare Logistics: New Balances to Win the Challenge of Capacity’ of the Contract Logistics Observatory of the Milan Polytechnic, which took place this morning. Not only. Phse, which the manager described as a “market leader” in particular in the segment of products in the 2°-8° temperature range, will develop its strength in that relating to shipments in the 15°-25° range to hospitals with the entry into the fleet, from March, of 101 dedicated vehicles.

The investments of the company controlled by Eddy De Vita and indirectly participated by Nb Aurora will not be limited to physical assets, however, but will touch the technological sphere, given that, added Gagliardi La Gala, Phse plans to implement an eQms system (for the digitalised and paperless management of quality processes) during the year, as well as to extend the use of RFID codes to every single parcel (and no longer therefore to every shipment or pallet). “We think this is the way to go in order to receive big data that can be used in the future not only for product tracking, but also to develop projects for transport planning, also using artificial intelligence”.

Returning to the results of the research presented during the morning, the manager also said that he “found himself in the trends” exposed, both in terms of the increase in production costs, especially those for the energy needed to maintain the plants (80 per cent of the company’s plants are at 2°-8°), of fuels and packaging, and in relation to the growth in shipments, which in the case of Phse was 9%, with peaks particularly in the Triveneto and Campania regions, and reached +35% for the 15°-25° range, which as seen, the company is now supporting with new investments.

Fonte: articolo Supply Chain Italy

Join us on 15th-16th March at NH Milano Congress Centre for #CTSEurope Clinical Trial Supply Event Series, co-hosted with Temperature Controlled Logistics in Biopharmaceuticals Europe, where you can meet with PHSE experts at stand #56 to explore our global clinical trial logistics solutions, from pre-clinical to compassionate use. We are looking for to meeting you! Vieni a trovarci al prossimo Clinical Trial Supply Europe 2023, 15-16 Marzo, stand #56! We are looking for to meeting you!

Register here: https://lnkd.in/dAbpZA9R
Use Reference Code: KGMK

PHSE, a leading company in pharmaceutical logistics, controlled by Eddy De Vita, executive president and majority shareholder, and participated by NB Aurora – which indirectly holds a 30,8% stake – in addition to the three founding partners, announces that it has signed an agreement for the acquisition of 70% of Transporte de Carga Biologica Express Ltda “Bio Transportes”, a Brazilian company specializing in the temperature-controlled transport of materials for clinical trials, drugs and vaccines, with a strong focus on the distribution of biological samples and bone marrow. The founders of the company, Vanessa and Sandra Rodrigues, will retain a 30% stake and will continue to manage the business.

Through this transaction, PHSE, which in 2021 recorded consolidated revenues of around 45 million euros, up 40% compared to 2020, is able to further expand the Group’s presence abroad, offering increasingly global solutions for the cold chain of the healthcare sector.

Bio Transportes, based in São Paulo, was founded in 2011 by the sisters Vanessa and Sandra Rodrigues, becoming, in just over ten years, a reference service provider for the specialist distribution, by land and by air, of biological samples, clinical trials and drugs on behalf of the main research and development organizations in Brazil. As well as its headquarters in São Paulo, the company also has branches in Ribeiro Preto, Curitiba, Recife, and Goiania.

Bio Transportes is IATA certified, and has a diverse (65% female employees) and inclusive culture, which is a particular strength of the company.

Its vehicle fleet, mainly specialist vans, meets the regulatory requirements of the pharmaceutical industry. Vehicles are equipped with GPS satellite detection systems capable of collecting continuous information on the position and temperature of the vehicle (constantly recorded by probes installed inside the load compartment), made available in real time on a dedicated tracking platform. There is also a fleet of motorbikes with which the company offers an express urban delivery service in the São Paulo area.

This is the fourth acquisition made by PHSE since the beginning of 2021, the third abroad after TEK Freight in the United Kingdom, and the Rapida Time & Temperature in India, expanding its global network to support its customers.

“Our skills in the sector create an ideal platform to fully realize the potential of Bio Transportes which in the next few years will continue in its development plan which foresees the opening of other platforms in Porto Alegre, Rio de Janeiro and Fortaleza” said Eddy De Vita, Executive President, PHSE. “We are very proud of what we have achieved to date, but, as part of the PHSE Group will now be able to provide a broader range of services to our customers in Brazil”, said Sandra Rodrigues, Bio Transportes.

For the current year, the Group expects a further increase in revenues, driven both by the new acquisitions and the strong development of traditional businesses like Global Forwarding and Home Care, as well as the commencement of new activities, such as the transport of radiopharmaceuticals.

Fonte: PHSE press release

PHSE, leading company in pharmaceutical logistics, strengthens its presence in the italian market through the acquisition of Duimex, active in temperature-controlled transport of clinical trials, biological samples and in the management of “special services”

PHSE, a leading company in pharmaceutical logistics controlled by entrepreneur Eddy De Vita and participated in by NB Aurora – which indirectly holds a 30.8% stake – as well as by the three founding partners Andrea Cerchia, Carlo Cerchia and Gianluca Meneguzzi, announces that it has acquired the 100% of Duimex, an Italian company based in Peschiera Borromeo, active in national and international temperature-controlled transport, with strong specialization in the logistics of “same day” special services, clinical trials and biological samples.

Since 1996 Duimex has served the research, clinical, diagnostic and hospital community extensively. Its distribution capability is made up of 45 direct employees, a refrigerated GDP logistics hub on the outskirts of Milan and 40 temperature-controlled vehicles, through which Duimex provides highly specialized services ranging from the transport of life-saving pharmaceutical products to the the delicate transfer of stem cells to patients. Duimex closed 2020 reaching revenues of around 3.4 million euros, 70% of which with hospitals and diagnostic centers, confirming a constant growth trend in recent years.

The transaction was concluded a few months after the recent acquisitions of the English Tek Freight and the Rapida Time & Temperature in Indiaconfirming a strong acceleration in the expansion of its global network, but also a strong focus on strengthening its portfolio of high value added services in support of pharmaceutical research and clinical studies, where Italy in particular plays an important and growing role with more than 700 million euros per year invested by the pharmaceutical industry.

Duimex’s skills will allow PHSE Group, which has always been a pioneer in biopharmaceutical logistics, to expand its clientele in the public and private hospital sector and to further strengthen its operational, organizational and technological base, as well as providing an increasingly “data-centric” service to its customers: research institutes, laboratories, experimental centers, pharmaceutical companies and blood banks.

Duimex, in line with the regulatory requirements of the pharmaceutical industry, in particular related to the guarantee of traceability and compliance with temperature, has fleet of vehicles, all equipped with a self-contained refrigerating unit bulkhead and with GPS satellite detection systems capable of collecting continuous information on the position and temperature of the vehicle (constantly recorded by probes installed inside the load compartment), made available in real time on a dedicated tracking platform.

Eddy De Vita, Presidente di PHSE, has commented : “With around 300 products under development, pharmaceutical research in Italy is increasingly specialized in biotechnologies, vaccines, blood products, orphan drugs and advanced therapies and plays an increasing role in clinical trials. These products require fast logistics, very attentive to the requirements of temperature stability and safe, we are talking about very high value therapies. The entry of Duimex’s skills into the PHSE family will strengthen our presence in the special services and clinical trials segment and will represent an important step in the development plan of the PHSE business towards supply chain solutions that are able to support the evolution of the Healthcare industry and patient access to innovative drugs.”

In order to give continuity to Duimex’s capabilities, the company will maintain its management autonomy. PHSE has fully confirmed the confidence in its business model which, like PHSE, is based on the management of transport with directly employed staff and owned vehicles.